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Abstract 
The inefficacity of the actual therapies for glioblastoma multiformis stimulates the researchers to search for 
new and innovative therapies. Therefore, the development of in vivo model for glioblastoma is an essential step during 
these researches, being a link between cells cultures studies and the first phases of clinical trials. 
In this paper, we present several procedures which have been performed for the first time in our country, such 
as: the cultivation and manipulation of U87MG line, the manipulation of athymic – knock-out mice (NUDE Crl: CD-1 
Foxn1), the stereotactic inoculation of glioblastoma cells and finally the development of glioblastoma xenograft in the 
brain of inoculated nude mice.  
These results, which offer to the researchers from our country an in vivo model for glioblastoma, could be the 
start  point  for  several  projects  oriented  to  the  development  of  new  therapies  in  glioblastoma,  and  could  raise  the 
performance of our scientific research to the European level. 
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Introduction 
 
Glioblastoma  multiformis  is  the  most  malignant  primary  brain  tumor  in  adult.  The  life 
expectation  for  a  patient  with  glioblastoma  does  not  usually  exceed  one  year.  In  spite  of  the 
complex treatment applied (neurosurgical resection, radiotherapy, chemotherapy), the outcome is 
extremely poor, with 100% mortality. The inefficiency of actual therapies stimulates the researchers 
toward the direction of discovering new innovative therapies. Therefore, the development of in vivo 
model for glioblastoma represents an essential step during these researches, being a link between 
the cells cultures studies and the first phases of clinical trials. 
In  this  paper  the  authors  present  for  the  first  time  in  Romania,  the  development  of 
glioblastoma  xenograft  in  nude  mice.  Several  materials  and  procedures  have  been  acquired  or 
performed for the first time in our country, such as: the cultivation and manipulation of U87MG 
line (an international glioblastoma line brought for the first time in Bucharest), the breeding and 
manipulation of athymic – knock-out mice (NUDE Crl: CD-1 Foxn1, acquired from Charles River 
laboratories),  the  stereotactic  inoculation  of  glioblastoma  cells  and  finally  the  development  of 
glioblastoma  in  the  brain  of  nude  mice,  proved  by  histopathological  studies  and 
immunohistochemistry images. 
This  achievement  is  the  result  of  the  collaboration  between  the  research  department  in 
neuroscience of the Clinical Hospital “Bagdasar-Arseni”, the National Institute of Virology “Stefan 
S. Nicolau” and Department of Histology of University of Bucharest. The experiments have been 
supported by the national research grant CEEX-VIASAN, no.176/2006. 
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Material  
 
Glioblastoma line 
The glioblastoma line, U87MG, has been acquired from the European Collection of Cell 
Cultures  (ECACC).  This  line  has  been  cultivated  and  frozen  in  several  research  centers  in 
Bucharest: Department of basic research in neuroscience from Clinical Hospital “Bagdasar-Arseni”, 
National Institute of Virusology “Stefan S. Nicolau” and National Institute of Biological Sciences. 
This line has the following characteristics (according to ECACC description): 
- Cell Line Name: U87MG 
- Cell Line Description: derived from a malignant glioma from a female patient by explant 
technique. It is reported to produce a malignant tumour consistent with glioblastoma in nude mice. 
- Species: Human 
- Tissue: Brain 
- Morphology: Epithelial-like 
- Sub Culture Routine: Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-
4x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. 
- Culture Medium: EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids 
(NEAA) + 1mM Sodium Pyruvate (NaP) + 10% Foetal Bovine Serum (FBS). 
- Karyotype: 2n = 46  
   - Markers: Positive for GFAP 
- Receptors: Over expression of EGFR 
 
 
                   
 
Fig 1: Microscopical aspects of Glioblastoma line U 87 
(Inverted microscope, X20) 
 
Green fluorescence protein gene (GFAP) transfection  
Transfection  method  involved  lipofectamin,  according  to  the  manufacturer's  protocol 
(Invitrogen). The type of vector is shuttle: it can replicate in prokaryote and in eukaryote also. Cells 
were mixed together with plasmidic DNA (vector with GFAP gene) and lipofectamine in 6 wells – 
one million cells/well. Then they were kept for 24 h at 37ºC. The GFAP expression was evaluate at 
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                            Fig 2: U 87 cells transfected with GFP – visualized at fluorescence microscope 
 
Nude Mice 
The athymic mice (nude mice) were acquired from the Charles River laboratories Germany. 
The full name of this line is: NUDE Crl: CD-1 Foxn1 and was obtained by successive transfers of 
the nude gene into mice CD-1. These mice are athymic and have albinos, hairless phenotype. 
 
              
  
                                      Fig.3: The phenotype of the nude mice used in our experiments 
 
Comparing with the other line of the Charles River laboratories, this line has the following 
characteristics: 
 
Line/characteristic  Hair  Thymus  T-cells  B-cells  NK cells  Fix 
complement 
CD1 nude  -  -  -  +  +  + 
Nu/Nu nude  -  -  -  +  +  + 
Balbc/nude  -  -  -  +  +  + 
NIH-III nude  -  -  -  -  -  + 
Fox Chase SCID  +  +  -  -  +  + Journal of Medicine and Life  Vol. 1, No.3, July-September 2008 
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Instruments 
For the scalp incision we used a set of micro-surgical forceps, scissors and grips (Aesculap, 
Germany).  
 
      
 
 
                                Fig.4: Micro-instruments used for surgical experiments 
 
In order to make the burr whole in the skull as small as possible, we used a special electric 
drill system (TC-Motor 3000, Nouvag, Switzerland). This system has an electronic control of the speed 
and uses small drills (1mm diameter). 
 
 
                                                   
                                                   Fig.5: Micro-motor TC-Motor 3000 
 
The inoculation of the glioblastoma cells have been performed stereotactically with a special 
stereotactic system (TAXIC-600 - WPI Stereotaxic Frame 18 deg. Ear Bars and UMP 3-1 injection 
system), (World Precision Instruments, Germany). This system enables researchers to inoculate 
very small volumes of glioblastoma cells suspension (3 micro liters) during a controlled period of 
time (3 minutes) very precisely, targeting the same structures of the mice brain. Journal of Medicine and Life  Vol. 1, No.3, July-September 2008 
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Fig 6: Stereotaxic system: TAXIC-600 - WPI Stereotaxic Frame 18 deg. Ear Bars and UMP 3-1 injection system, 
(World Precision Instruments, Germany). 
 
Methods 
 
 Anesthetic technique 
After we had tried several anesthetic techniques described in the literature, we selected the most 
efficient  and  easy  to  administered  one.  This  is  a  combination  of  ketamine  (between  80  and 
100mg/kg)  and  xylazine  (10mg/kg).  These  drugs  are  combined  in  the  same  syringe  and  are 
administered intraperitoneally.  The anesthetic effect is obtained within 5 minute after the drugs 
administration.  The  effect  lasts  between  20  and  30  minutes,  and  produces  a  good  muscular 
relaxation and doesn’t required any specific parameters controls (respiration, cardiac monitoring). 
 
Agent  Doze  Anesthetic period 
Pentobarbital  50 mg/kg IP  20-40 minutes 
Tribromoethanol 
(avertin)  240 mg/kg IP  15-45 minutes 
Metomidate/fentanyl  60 mg/kg + 0.06 mg/kg 
SC  20-30 minutes 
Ketamine/xylazine  80-100 mg/kg + 10 
mg/kg IP   20-30 minutes 
 
Inoculation technique 
We used as anatomical landmark bregma, which is easy to be recognized after skin incision. 
The burr whole is performed 3mm lateral and 1mm in front of the bregma, using a small 
drill (1mm diameter). 
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Fig.7: The main anatomical landmarks 
 
Then  we  introduce  stereotactically  the  needle  of  the  Hamilton  syringe  until  a  depth  of 
3,5mm from dura mater, with a 30 grades tilt of the needle in the coronal plane from laterally to 
medially.  
 
 
 
Fig. 8: Inoculation of trypane blue in order to demonstrate the site of inoculation - coronal section of the mouse 
brain 
 
The  next  step  is  to  inoculate,  within  3min,  approximately  500.000  glioblastoma  cells, 
suspended in 3L, using the electronic control of the injection system. The needle is left in place for 
one more minute after finishing the cells inoculation then is removed slowly. We applied sterile 
wax inside the bur whole then sutured the scalp.   
 
 
 
 Fig. 9: Mouse post-inoculation–aspect of scalp incision Journal of Medicine and Life  Vol. 1, No.3, July-September 2008 
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We established two lots: 
- Lot I (20 mice). For this lot we inoculated 5×10
5 U87 native glioblastoma cells 
- Lot II (10 mice). In this lot we inoculated 5×10
5 U87 glioblastoma cells transfected with 
GFP gene. 
The samples (mice brains) were obtained for both lots at specific intervals post-inoculation: 
7 days, 14 days, 21 days and 28 days. Two mice, one for each lot, die at 24 post-inoculation. One 
mice of the lot I died spontaneously at 27 days. When the skull was opened the tumor developed 
and occupied more then a half of the hemisphere; this was probably the cause of mouse death. 
All  the  animal  manipulations  have  been  performed  in  accordance  with  national  and 
international guidelines.  
The samples have been sent to the Department of Histology of the University Bucharest in 
order to be performed the histology and immunohistochemistry studies. 
 Histology: For morphologic analysis, mice brains were fixed in 4% formaldehyde in PBS, 
embedded in paraffin and 5-micrometer coronal sections were prepared. Sections were also stained 
with DAPI (4′,6-diamidino-2-phenylindole) (1g/mL) to visualize the nuclei. Fluorescent signals by 
either GFP or DAPI were examined under the fluorescence microscope (Zeiss Axiostar Plus). 
The Immunohistochemistry studies: 8m-thick sections were sequentially incubated in 3% 
H2O2 to remove endogenous peroxidase (10 min), washed PBS and incubated with 2% bovine 
serum albumin (BSA, fraction V) to remove non-specific background staining (30 min). Sections 
were incubated overnight, at 4
0C with rabbit anti human 2 microglobulin peroxidase conjugated 
(Biomol), diluted 1:50, rinsed with PBS and incubated for 10-15 min in a solution of 0.05% 3,3’-
diaminobenzidine  tetrachloride  (DAB)  and  0.015%  hydrogen  peroxide,  dissolved  in  PBS.  The 
nuclei were counterstained with haematoxylin (blue). 
Coverslips with glioblastoma cells were rinsed four times with cold PBS and fixed in 4% 
formaldehyde in PBS. Fixed cells were washed in PBS and incubated with 2% BSA to remove non-
specific background staining (30 min). The cells were subsequently incubated overnight at 4°C with 
mouse monoclonal anti Glial Fibrillary Acidic Protein (GFAP), primary antibody (Sigma), diluted 
1:150, followed by rinses in PBS and incubation with a secondary HRP-conjugated rabbit anti-
mouse antibody (Rockland), diluted 1:400 (1h, at room temperature). 
The photomicrographs were taken by digital camera (AxioCam MRc 5, Carl Zeiss) driven 
by software AxioVision 4.6 (Carl Zeiss).   
 
Results 
 
The  macroscopic  and  microscopic  images  performed  at  7  days  after  glioblastoma 
inoculation,  have  shown  the  tumor  developed  at  the  injection  site,  near  the  wall  of  the  lateral 
ventricle in the right hemisphere. (Fig. 10).  
 
                    
 
Fig. 10A-B. Macroscopic (10A) and microscopic (10 B – inverted image) aspect of the glioblastoma 
xenograft at 7 days postinoculation (arrow). Colored with hematoxilin-eosin. 
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In fluorescence microscopy, the tumor is characterized by the presence of the following 
characteristics:  hypercellularity,  nuclear  atypical  aspect,  aberrant  mitotic  figures  and  gigantic 
multinucleate cells (Fig.11-13). 
 
 
 
 
Fig. 11: The fluorescence microscopic aspect of the GFP transfected glioblastoma cells at 3 days post -inoculation. 
Computerized system acquisition has been used for this image. 
 
 
 
Fig.12. Tumor characterized by hyper-cellurality. Image taken at 7 days post inoculation (Colored with DAPI). 
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Fig.13. Multinucleate gigantic cells (arrow) Image taken at 7 days post inoculation (Colored with DAPI).  
 
 
At 28 days post inoculation, the tumor is very large, occupying almost a half of the right cerebral 
hemisphere (Fig.14 ). 
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Fig. 14. The glioblastoma induced tumor at 28 days post-inoculation (14 A). The microscopic aspect (14 B). Colored 
with hematoxilin-eozina. 
 
Discussions 
 
The poor prognosis of glioblastoma orientated the researcher to the direction of developing 
new molecular and cellular therapies. The first step in discovering new therapeutically agents is to 
test these on in vitro model of standardized glioblastoma cells cultures. The authors of this paper 
have succeeded for the first time in Romanian to develop a new glioblastoma cells line – T11 (more 
then 150 passages, characterized glioblastoma line) [1]. 
When an agent proved its efficacy on culture cells, the next step is to test this substance on 
animal  model.  Therefore,  the  development  of  an  in  vivo  model  is  absolutely  necessary,  as  an 
intermediate stage between in vitro experiments and the first phase of a clinical trial. 
In order to develop the tumor in mice, using a human glioblastoma line, like U87MG, the 
animal should have the immune system “switched-of”. Thus, all the mice used for developing the 
model of glioblastoma are knock-out mice for a special gene – the FOX 1 gene. These mice are 
athymic mice and have severe deficiency in the production of T cells. The immunodeficiency of the 
mouse allows the inoculated human glioblastoma cells to develop the glioblastoma xenograft inside 
their body. The therapeutic response of various agents to brain tumor cell lines is frequently tested 
in  immunodeficient  mice  following  subcutaneous  or  intracerebral  injection.  The  subcutaneous 
injection  allows  one  to  evaluate  the  response  to  treatment  by  simply  sacrificing  the  animal  at 
specific time intervals and measuring the size of the tumor, a technique that requires the use of a 
large number of animals and adds to the cost. However, a more frequently used method is to inject 
the mice intracerebral and to asses the volume of the developed tumor by scarified the animals at 
specific period of time. 
The  experimental  intracranial  injection  techniques  previously  reported  [2-12]  do  not 
necessarily  or  accurately  assess  the  following  parameters:  the  number  of  cells  injected,  their 
viability after injection, the degree of anatomical disruption of the injection site, whether the tumor 
cells are confined to the parenchyma or have been injected into the ventricles. Yamada et al (2004) 
(13) described in details several techniques aspects of injecting the gliobastoma cells in mice brain. 
First  they  define  very  precisely  the  target  of  the  injection,  then  they  assess  the  volume  of 
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glioblastoma cells, which should nod exceed the 3L, and the time of injection, not less then 3 
minutes. Following these useful data, found in the literature, the authors established the protocol of 
inoculation before starting the experiments. Therefore, the basal ganglia was defined as the target 
area, using the landmarks previously described then 3L of glioblastoma cells suspension has been 
injected within 3 minutes. Using this method the mortality of the mice included in this study was 
low (10%) and the rate of success in developing the glioblastoma xenograft was high (90%). 
Interestingly, Castro et al (2007) recently suggested that the number of U87cells required for 
developing the glioblastoma in nude mice is about 1 million cells [14]. However, in the experiments 
described  above,  authors  succeeded  to  develop  the  glioblastoma  using  only  500.000 
cells/inoculation, even they used the same materials and methods as Castro et al. 
The  characteristic  of  glioblastoma  xenograft  developed  by  authors  were  close  to  those 
described previously in literature (5, 7, 14). The authors performed classic microscopic studies, 
immunohistochemistry studies and microscopic fluorescence studies. The quality of images taken 
by a performing microscope and a digital acquisition system proved the success of the model, and 
ensure the reproducibility of the experiments. 
 
Conclusions 
 
The authors of this paper managed to develop for the first time in Romania glioblastoma 
xenograft  in  nude  mice.  The  experiments  were  reproducible  with  a  high  rate  of  success. 
Establishing  an  in  vivo  model  for  gliobastoma,  authors  proved  that  the  collaboration  between 
clinical  hospitals  and  researcher  institute  is  very  important  for  developing  new  experimental 
models. Therefore, this achievement could be the start point for developing new projects and new 
experiments  in  order  to  find  innovative  therapies  for  glioblastoma.  Testing  newly  discovered 
therapeutically  agents  on  in  vivo  models  will  offer  the  researchers  more  secure  in  using  these 
substances on human in clinical trials, and could be a link between fundamental researcher and 
clinical research. 
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